X0306 4 2016-10-31 0 0001481512 Ra Pharmaceuticals, Inc. RARX 0001270521 KOLLURI KRISHNA KITTU 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 0 0 1 0 Common Stock 2016-10-31 4 X 0 80658 0.07 A 80658 I See Note 2 Common Stock 2016-10-31 4 S 0 435 13.00 D 80223 I See Note 2 Common Stock 2016-10-31 4 C 0 1778227 A 1858450 I See Note 2 Common Stock 2016-10-31 4 C 0 669951 A 2528401 I See Note 2 Common Stock 2016-10-31 4 C 0 623210 A 3151611 I See Note 2 Common Stock 2016-10-31 4 P 0 338462 13.00 A 3490073 I See Note 2 Warrants to Purchase Common Stock 0.07 2016-10-31 4 X 0 80658 0.00 D 2022-04-01 Common Stock 80658 0 I See Note 2 Series A Preferred Stock 2016-10-31 4 C 0 12447605 0.00 D Common Stock 1778227 0 I See Note 2 Series B-1 Preferred Stock 2016-10-31 4 C 0 4689657 0.00 D Common Stock 669951 0 I See Note 2 Series B-2 Preferred Stock 2016-10-31 4 C 0 4362472 0.00 D Common Stock 623210 0 I See Note 2 The Warrants automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 435 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 80,223 shares, after deducting the aggregate exercise price. The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of New Enterprise Associates 13, L.P. ("NEA 13"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 shares in which the Reporting Person has no pecuniary interest. Each share of the Series A Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date. Each share of the Series B-1 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date. Each share of the Series B-2 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date. /s/ Sasha Keough, attorney-in-fact 2016-10-31